XML 35 R18.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Common Stock | 12 Months Ended
--- | ---
Dec. 31, 2017
Equity [Abstract] |
Common Stock | 12. COMMON STOCK [a] Authorized 75,000,000 authorized common voting share, par value of $0.001, and 5,000,000 preferred shares, par value of $0.001. [b] Issued and outstanding shares Purchase Agreement and Financing with Lincoln Park Capital On September 14, 2017 we and Lincoln Park Capital Fund, LLC, or LPC, entered into a share and unit purchase agreement, or Purchase Agreement, pursuant to which we have the right to sell to LPC up to $11.0 million in shares of our common stock, par value $0.001 per share, subject to certain limitations and conditions set forth in the Purchase Agreement. Pursuant to the Purchase Agreement, LPC initially purchased 328,947 of our units, or the Units, at a purchase price of $3.04 per unit, with each Unit consisting of (a) one share of our Common Stock and (b) one warrant to purchase one-quarter of a share of Common Stock at an exercise price of $3.496 per share, or Warrant. Each Warrant is exercisable six months following the issuance date until the date that is five years and six months after the issuance date and is subject to customary adjustments. The Warrants were issued only as part of the Units in the initial purchase of $1.0 million and no warrants shall be issued in connection with any other purchases of common stock under the Purchase Agreement. After the initial purchase, if our stock price is above $1.00, as often as every other business day over the 30-month term of the Purchase Agreement, and up to an aggregate amount of an additional $10.0 million (subject to certain limitations) of shares of common stock, we have the right, from time to time, in our sole discretion and subject to certain conditions to direct LPC to purchase up to 80,000 shares of common stock with such amounts increasing as the closing sale price of our common stock as reported on The NASDAQ Capital Market increases. The purchase price of shares of common stock pursuant to the Purchase Agreement will be based on prevailing market prices of common stock at the time of sales without any fixed discount, and we will control the timing and amount of any sales of common stock to LPC. In addition, we may direct LPC to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the common stock is not below $2.00 per share. As consideration for entering into the Purchase Agreement, we issued to LPC 123,516 shares of common stock; no cash proceeds were received from the issuance of these shares. From September 14, 2017 through December 31, 2017, we offered and sold 873,778 shares of our common stock pursuant to our Purchase Agreement with LPC, including the 328,947 shares that were part of the initial purchase of Units. These sales resulted in gross proceeds to us of approximately $2.0 million and offering expenses of $0.1 million. As of December 31, 2017 shares of our common stock having an aggregate value of approximately $9.0 million remained available for sale under this offering program. Equity Award Issuances and Settlements During the year ended December 31, 2017, we did not issue any shares of common stock to satisfy stock option exercises and issued 5,464 shares of common stock to satisfy restricted stock unit settlements, respectively, compared with the issuance of no shares of common to satisfy stock option exercises and restricted stock unit settlements, respectively, for the year ended December 31, 2016. [c] Stock options 2017 Equity Incentive Plan As of December 31, 2017, we had reserved, pursuant to the 2017 Equity Incentive Plan, or the 2017 Plan, 1,052,200 common shares for issuance upon exercise of stock options, currently outstanding, by employees, directors and officers of ours. Under the 2017 Plan, we may grant options to purchase common shares or restricted stock units to our employees, directors, officers and consultants. The exercise price of the options is determined by our board of directors but will be at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our board of directors. The expiry date for each option is set by our board of directors with a maximum expiry date of ten years from the date of grant. In addition, the 2017 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. 2010 Performance Incentive Plan As at December 31, 2017 we had reserved, pursuant to our 2010 Performance Incentive Plan, 68,507 common shares for issuance upon exercise of stock options and settlement of restricted stock units by employees, directors, officers and consultants of ours, of which 63,447 are reserved for options currently outstanding and 5,060 are reserved for restricted stock units currently outstanding. Under the 2010 Plan we granted options to purchase common shares and restricted stock units to our employees, directors, officers and consultants. The exercise price of the options was determined by our board of directors and was at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our board of directors. The expiry date for each option is set by our board of directors with a maximum expiry date of ten years from the date of grant. In addition, the 2010 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees ASC 718 Compensation – Stock Compensation We recognize expense related to the fair value of our stock-based compensation awards using the provisions of ASC 718. We use the Black-Scholes option pricing model as the most appropriate fair value method for our stock options and recognize compensation expense for stock options on a straight-line basis over the requisite service period. In valuing our stock options using the Black-Scholes option pricing model, we make assumptions about risk-free interest rates, dividend yields, volatility and weighted average expected lives, including estimated forfeiture rates of the options. The expected life was calculated based on the simplified method as permitted by the SEC’s Staff Accounting Bulletin 110, Share-Based Payment. We consider the use of the simplified method appropriate because of the lack of sufficient historical exercise data following the reverse merger of OncoGenex. The computation of expected volatility was based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a U.S. Treasury instrument whose term is consistent with the expected life of the stock options. In addition to the assumptions above, as required under ASC 718, management made an estimate of expected forfeitures and is recognizing compensation costs only for those equity awards expected to vest. Forfeiture rates are estimated using historical actual forfeiture rates. These rates are adjusted on a quarterly basis and any change in compensation expense is recognized in the period of the change. We have never paid or declared cash dividends on our common stock and do not expect to pay cash dividends in the foreseeable future. The estimated fair value of stock options granted in the respective periods was determined using the Black-Scholes option pricing model using the following weighted average assumptions:
|  | 2017 |  |
Risk-free interest rates |  |  | 1.95 | % |
Expected dividend yield |  |  | 0 | % |
Expected life |  | 6 years |  |
Expected volatility |  |  | 86.06 | % |
The weighted average fair value of stock options granted during the year ended December 31, 2017 was $2.09. The results for the periods set forth below included stock-based compensation expense in the following expense categories of the consolidated statements of loss (in thousands):
|  | Year ended
|  | December 31,
|  | 2017 |  |
Research and development |  | $ | 107 |  |
General and administrative |  |  | 241 |  |
Total stock-based compensation |  | $ | 348 |  |
Options vest in accordance with terms as determined by our board of directors, typically over three or four years for employee and consultant grants and over one or three years for board of director option grants. The expiry date for each option is set by our board of directors with, which is typically seven to ten years. The exercise price of the options is determined by our board of directors but is at least equal to the fair value of the share at the grant date. Stock option transactions and the number of stock options outstanding are summarized below:
|  | Number of |  |  | Weighted |
|  | Optioned |  |  | Average |
|  | Common |  |  | Exercise |
|  | Shares |  |  | Price |
Balance, January 1, 2017 |  | $ | — |  |  | $ | — |
Additions from OncoGenex Plan |  |  | 113,451 |  |  |  | 96.38 |
Granted |  |  | 1,052,200 |  |  |  | 2.89 |
Expired |  |  | (19,543 | ) |  |  | 114.53 |
Exercised |  |  | — |  |  |  | — |
Forfeited |  |  | (30,461 | ) |  |  | 92.72 |
Balance, December 31, 2017 |  |  | 1,115,647 |  |  | $ | 7.99 |
The following table summarizes information about stock options outstanding at December 31, 2017 regarding the number of ordinary shares issuable upon: (1) outstanding options and (2) vested options. (1) Number of common shares issuable upon exercise of outstanding options:
|  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  |  |  |  |  | Remaining |
|  |  |  |  |  | Weighted- |  |  | Contractual |
|  |  |  |  |  | Average |  |  | Life |
Exercise Prices |  | Number of Options |  |  | Exercise Price |  |  | (in years) |
$2.89 - $6.95 |  |  | 1,052,200 |  |  | $ | 2.89 |  |  |  | 9.58 |
$6.96 - $15.73 |  |  | 4,090 |  |  |  | 11.00 |  |  |  | 8.40 |
$15.74 - $20.63 |  |  | 17,983 |  |  |  | 20.46 |  |  |  | 7.38 |
$20.64 - $37.35 |  |  | 6,452 |  |  |  | 31.53 |  |  |  | 6.76 |
$37.36 - $128.64 |  |  | 2,451 |  |  |  | 84.08 |  |  |  | 5.75 |
$128.65 - $130.57 |  |  | 8,905 |  |  |  | 129.69 |  |  |  | 6.20 |
$130.58 - $134.81 |  |  | 6,450 |  |  |  | 131.45 |  |  |  | 5.19 |
$134.82 - $143.88 |  |  | 5,927 |  |  |  | 142.41 |  |  |  | 4.36 |
$143.89 - $185.85 |  |  | 7,019 |  |  |  | 172.70 |  |  |  | 3.01 |
$185.86 - $245.08 |  |  | 4,170 |  |  |  | 237.60 |  |  |  | 2.21 |
|  |  | 1,115,647 |  |  | $ | 7.99 |  |  |  | 9.37 |
(2) Number common shares issuable upon exercise of vested options:
|  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  |  |  |  |  | Remaining |
|  |  |  |  |  | Weighted- |  |  | Contractual |
|  |  |  |  |  | Average |  |  | Life |
Exercise Prices |  | Number of Options |  |  | Exercise Price |  |  | (in years) |
$2.89 - $6.95 |  |  | 3,644 |  |  | $ | 2.89 |  |  |  | 9.58 |
$6.96 - $15.73 |  |  | 4,090 |  |  |  | 11.00 |  |  |  | 8.40 |
$15.74 - $20.63 |  |  | 14,883 |  |  |  | 20.46 |  |  |  | 7.38 |
$20.64 - $37.35 |  |  | 5,432 |  |  |  | 31.25 |  |  |  | 6.77 |
$37.36 - $128.64 |  |  | 2,451 |  |  |  | 84.08 |  |  |  | 5.75 |
$128.65 - $130.57 |  |  | 8,758 |  |  |  | 129.69 |  |  |  | 6.20 |
$130.58 - $134.81 |  |  | 6,450 |  |  |  | 131.45 |  |  |  | 5.19 |
$134.82 - $143.88 |  |  | 5,927 |  |  |  | 142.41 |  |  |  | 4.36 |
$143.89 - $185.85 |  |  | 7,019 |  |  |  | 172.70 |  |  |  | 3.01 |
$185.86 - $245.08 |  |  | 4,170 |  |  |  | 237.60 |  |  |  | 2.21 |
|  |  | 62,824 |  |  | $ | 91.79 |  |  |  | 5.95 |
As at December 31, 2017, the total unrecognized compensation expense related to stock options granted was $2.0 million, which is expected to be recognized into expense over a period of approximately 3.9 years. The estimated grant date fair value of stock options vested during the years ended December 31, 2017, 2016 and 2015 was $0.6 million, zero and zero, respectively. The aggregate intrinsic value of options exercised was calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock as of the date of exercise. The aggregate intrinsic value of options exercised for the years ended December 31, 2017, 2016 and 2015 was zero, zero and zero, respectively. At December 31, 2017, the aggregate intrinsic value of the outstanding options was zero and the aggregate intrinsic value of the exercisable options was zero. [d] Restricted Stock Unit Awards We grant restricted stock unit awards that generally vest and are expensed over a four year period. We also grant restricted stock unit awards that vest in conjunction with certain performance conditions to certain executive officers and key employees. At each reporting date, we are required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision. For the year ended December 31, 2017, $0.1 million of stock based compensation expense was recognized related to these awards. The following table summarizes our restricted stock unit award activity during the year ended December 31, 2017:
|  |  |  |  |  | Weighted |
|  | Number |  |  | Average |
|  | of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Balance, January 1, 2017 |  |  | - |  |  | $ | - |
Additions from OncoGenex Plans |  |  | 10,527 |  |  |  | 41.12 |
Granted |  |  | 205,100 |  |  |  | 2.89 |
Released |  |  | (5,464 | ) |  |  | 44.25 |
Forfeited or expired |  |  | (3 | ) |  |  | 25.37 |
Balance, December 31, 2017 |  |  | 210,160 |  |  | $ | 3.73 |
As of December 31, 2017, we had approximately $0.6 million in total unrecognized compensation expense related to our restricted stock unit awards which is to be recognized over a weighted-average period of approximately 3.75 years. [e] Stock Warrants The following is a summary of outstanding warrants to purchase common stock at December 31, 2017:
|  | Total |  |  |  |  |  |  |
|  | Outstanding |  |  | Exercise |  |  |
|  | and |  |  | price per |  |  |
|  | Exercisable |  |  | Share |  |  | Expiration Date
(1) Series A Warrants issued in July 2014 financing |  |  | 252,721 |  |  |  | 44.000 |  |  | July 2019
(2) Series B Warrants issued in July 2014 financing |  |  | 60,933 |  |  |  | 44.000 |  |  | July 2019
(3) Series A-1 Warrants issued in April 2015 financing |  |  | 21,748 |  |  |  | 26.400 |  |  | October 2020
(4) Warrants issued in September 2017 financing |  |  | 82,237 |  |  |  | 3.496 |  |  | March 2023
No warrants were exercised for the year ended December 31, 2017. The Series A-1 Warrants assumed by us as part of the Arrangement and the warrants issued in the September 2017 financing are classified as equity. The Series A and Series B assumed by us as part of the Arrangement are classified as liabilities. The estimated fair value of warrants classified as liabilities is reassessed at each reporting date using the Black-Scholes pricing model.
|  | As of |
|  | December 31, |
Series A and Series B Warrant Valuation Assumptions |  | 2017 |  |  | 2016 |
Risk-free interest rates |  |  | 1.82 | % |  |  | — |
Expected dividend yield |  |  | 0 | % |  |  | — |
Expected life |  | 1.50 years |  |  |  | — |
Expected volatility |  |  | 86 | % |  |  | — |
[f] 401(k) Plan We maintain a 401(k) plan. Our securities are not offered as an investment option. Our shares are prohibited for inclusion our 401(k) plan, as well as any match of our shares to employee contributions. [g] Loss per common share The following table presents the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share and share amounts):
|  | Years ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (10,583 | ) |  | $ | (1,234 | ) |  | $ | (828 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |
Weighted average number of common shares outstanding |  |  | 4,794,421 |  |  |  | 21,230 |  |  |  | 21,230 |
Basic and diluted net loss per common share |  | $ | (2.21 | ) |  | $ | (58.13 | ) |  | $ | (39.00 | )
As of December 31, 2017 a total of 1.7 million options, restricted stock units and warrants, respectively, have not been included in the calculation of potential common shares as their effect on diluted per share amounts would have been anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration